Related Experiment Video
Updated: Jun 15, 2026
07:22
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
9.2K
The Anti-Leukemic Potential of Bee Venom
Preeti Solanki1, Mohini Rana1, Karnail Singh Choudhary1
1Department of Biotechnology-UCRD, Chandigarh University, Mohali, Punjab, 140413, India.
International Journal of General Medicine
|December 15, 2025
Summary
Bee venom (BV) shows potential for treating leukemia, a blood cancer. Research indicates BV components effectively induce cancer cell death and inhibit survival pathways, offering a promising alternative or complementary therapy.
Area of Science:
- Apitherapy and Cancer Research
- Hematologic Malignancies
Background:
- Leukemia, a blood cancer characterized by abnormal leukocyte production, necessitates multimodal treatments like chemotherapy and immunotherapy.
- Current leukemia therapies face limitations including drug resistance, severe side effects, high costs, and genetic heterogeneity, driving the search for alternatives.
- Bee venom (BV) and its components, notably melittin, possess demonstrated anti-cancer properties, including apoptosis induction and cell membrane disruption.
Purpose of the Study:
- To review current in vitro research on the effectiveness of apitherapy (bee venom) in treating leukemia.
- To assess bee venom's potential as a standalone or adjunctive therapy for leukemia.
- To identify limitations in existing studies and explore future research directions, including synergistic effects and targeted delivery.
Main Methods:
- Systematic review of in vitro studies investigating bee venom's effects on various human leukemia cell lines (e.g., HL-60, K562, Jurkat).
- Analysis of bee venom's mechanisms of action, including apoptosis induction and inhibition of cell survival pathways (e.g., Akt/ERK).
- Evaluation of dose-time- and cell line-dependent efficacy of bee venom treatments.
Main Results:
- Bee venom demonstrated significant anti-leukemic activity across multiple leukemia cell lines in a dose- and time-dependent manner.
- Key bee venom component, melittin, exhibits potent pro-apoptotic and anti-proliferative effects against leukemia cells.
- Bee venom effectively inhibits crucial cell survival signaling pathways, suggesting a strong anti-cancer mechanism.
Conclusions:
- Bee venom is a potent candidate for leukemia treatment, exhibiting significant in vitro efficacy.
- Further research into synergistic combinations of bee venom with conventional therapies and targeted delivery systems is warranted.
- Apitherapy presents a promising avenue for novel leukemia treatment strategies, addressing limitations of current approaches.
Related Concept Videos
00:42Cross-reactivity
Overview
01:10Antibody Structure
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...